GLPG2222: Ph IIa ALBATROSS started

Galapagos began the double-blind, placebo-controlled Phase IIa ALBATROSS trial to evaluate 2 dose levels of once-daily oral GLPG2222 plus Kalydeco ivacaftor for 29 days in up to 35 patients with a del...